Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is among the most promising biotech stocks to buy according to hedge funds. According to a recent disclosure with the SEC, Assenagon Asset Management S.A. lifted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by a whopping 439.0% during the second quarter. Following the acquisition of 947,865 shares, the firm now owns 1,163,755 shares of the company’s stock, reflecting an investment worth $42,314,000 and ownership of about 1.23%. During the latest ...